Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03317899 · OUTCOME

Percentage of Participants Receiving Corticosteroids

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma · Source last updated 2025-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
Not reported
Time frame
Up to 60 days

What was measured

will be presented as percentage of number of subjects who had the treatment

Analysis population: Protocol initially stated that median number of days on corticosteroids will be summarized by treatment arm and compared using Wilcoxon rank sum tests up to 60 days; data reported as Steroids initiated percentage

Groups in this outcome

Group I (auto HSCT tbo-filgrastim)

Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies

Group II (auto HSCT)

Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group I (auto HSCT tbo-filgrastim)38
Group II (auto HSCT)39

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Group I (auto HSCT tbo-filgrastim)31.4Not reportedNot reportedNot reportedNot reported
Group II (auto HSCT)51.4Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    OTHER
    p Value
    0.089
    statistical Method
    Chi-squared
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    OTHER
    p Value
    0.089
    statistical Method
    Chi-squared
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        31.4
      2. group Id
        OG001
        value
        51.4
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    2. group Id
      OG001
      value
      39
    units
    Participants
description
will be presented as percentage of number of subjects who had the treatment
groups
  1. description
    Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies
    id
    OG000
    title
    Group I (auto HSCT tbo-filgrastim)
  2. description
    Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies
    id
    OG001
    title
    Group II (auto HSCT)
param Type
NUMBER
population Description
Protocol initially stated that median number of days on corticosteroids will be summarized by treatment arm and compared using Wilcoxon rank sum tests up to 60 days; data reported as Steroids initiated percentage
reporting Status
POSTED
time Frame
Up to 60 days
title
Percentage of Participants Receiving Corticosteroids
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice